Plasma matrix metalloproteinase 9 levels may predict endoleaks after endovascular aortic aneurysm repair

Angiology

Volumn 64, Issue 1, 2013, Pages 49-56

  Antoniou, George A ^a   Georgiadis, George S ^b   Antoniou, Stavros A ^c   Murray, David ^a   Smyth, J Vincent ^a   Serracino Inglott, Ferdinand ^a,d   Paraskevas, Kosmas I ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

aortic aneurysm; endoleak; endovascular aneurysm repair; matrix metalloproteinase 9

Indexed keywords

BIOLOGICAL MARKER; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE;

ABDOMINAL AORTA ANEURYSM; AORTA ANEURYSM; ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; ENDOLEAK; ENDOVASCULAR ANEURYSM REPAIR; ENZYME BLOOD LEVEL; HUMAN; PREDICTIVE VALUE; SYSTEMATIC REVIEW; THORACIC AORTA ANEURYSM; TREATMENT OUTCOME;

AORTIC ANEURYSM; BIOLOGICAL MARKERS; BLOOD VESSEL PROSTHESIS; ENDOLEAK; ENDOVASCULAR PROCEDURES; HUMANS; MATRIX METALLOPROTEINASE 9; PROSTHESIS FAILURE; TREATMENT OUTCOME;

EID: 84870946210     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712458537     Document Type: Article

References (46)

1. Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG;, EVAR trial participants. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet. 2004 ; 364 (9437). 843-848
2. Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med. 2004 ; 351 (16). 1607-1618 (Pubitemid 39350421)
3. De Bruin JL, Baas AF, Buth J, et al. Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med. 2010 ; 362 (20). 1881-1889
4. Schermerhorn ML, O'Malley AJ, Jhaveri A, Cotterill P, Pomposelli F, Landon BE. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. N Engl J Med. 2008 ; 358 (5). 464-474 (Pubitemid 351185802)
5. Mirza TA, Karthikesalingam A, Jackson D, et al. Duplex ultrasound and contrast-enhanced ultrasound versus computed tomography for the detection of endoleak after EVAR: systematic review and bivariate meta-analysis. Eur J Vasc Endovasc Surg. 2010 ; 39 (4). 418-428
6. Verhoeven EL, Oikonomou K, Ventin FC, et al. Is it time to eliminate CT after EVAR as routine follow-up?. J Cardiovasc Surg (Torino). 2011 ; 52 (2). 193-198
7. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003 ; 92 (8). 827-839 (Pubitemid 36542523)
8. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999 ; 274 (31). 21491-21494 (Pubitemid 129519680)
9. Mandal M, Mandal A, Das S, Chakraborti T, Sajal C. Clinical implications of matrix metalloproteinases. Mol Cell Biochem. 2003 ; 252 (1-2). 305-329 (Pubitemid 37220762)
10. Ailawadi G, Eliason JL, Upchurch GR. Current concepts in the pathogenesis of abdominal aortic aneurysm. J Vasc Surg. 2003 ; 38 (3). 584-588 (Pubitemid 41123227)
11. Wassef M, Baxter BT, Chisholm RL, et al. Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg. 2001 ; 34 (4). 730-738 (Pubitemid 33664926)
12. Antoniou GA, Georgiadis GS, Antoniou SA, Granderath FA, Giannoukas AD, Lazarides MK. Abdominal aortic aneurysm and abdominal wall hernia as manifestations of a connective tissue disorder. J Vasc Surg. 2011 ; 54 (4). 1175-1181
13. Antoniou GA, Tentes IK, Antoniou SA, et al. Circulating matrix metalloproteinases and their inhibitors in inguinal hernia and abdominal aortic aneurysm. Int Angiol. 2011 ; 30 (2). 123-129
14. Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T. Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-analysis. Interact Cardiovasc Thorac Surg. 2009 ; 9 (3). 437-440
15. Hellenthal FA, Bosch JA, Pulinx B, et al. Plasma levels of matrix metalloproteinase-9: a possible diagnostic marker of successful endovascular aneurysm repair. Eur J Vasc Endovasc Surg. 2012 ; 43 (2). 171-172
16. Monaco M, Stassano P, Di Tommaso L, Iannelli G. Response of plasma matrix metalloproteinases and tissue inhibitor of metalloproteinases to stent-graft surgery for descending thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2007 ; 134 (4). 925-931 (Pubitemid 47449699)
17. Lorelli DR, Jean-Claude JM, Fox CJ, et al. Response of plasma matrix metalloproteinase-9 to conventional abdominal aortic aneurysm repair or endovascular exclusion: implications for endoleak. J Vasc Surg. 2002 ; 35 (5). 916-922 (Pubitemid 44718559)
18. Sangiorgi G, D'Averio R, Mauriello A, et al. Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation. 2001 ; 104 (12 suppl 1). I288 - I295
19. Chaikof EL, Blankensteijn JD, Harris PL, et al. Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg. 2002 ; 35 (5). 1048-1060 (Pubitemid 46098517)
20. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009 ; 339: b2700
21. McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg. 1999 ; 29 (1). 122-127
22. Hovsepian DM, Ziporin SJ, Sakurai MK, Lee JK, Curci JA, Thompson RW. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol. 2000 ; 11 (10). 1345-1352
23. Nakamura M, Tachieda R, Niinuma H, et al. Circulating biochemical marker levels of collagen metabolism are abnormal in patients with abdominal aortic aneurysm. Angiology. 2000 ; 51 (5). 385-392 (Pubitemid 30317028)
24. Lindholt JS, Vammen S, Fasting H, Henneberg EW, Heickendorff L.. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. Eur J Vasc Endovasc Surg. 2000 ; 20 (3). 281-285
25. Watanabe T, Sato A, Sawai T, et al. The elevated level of circulating matrix metalloproteinase-9 in patients with abdominal aortic aneurysms decreased to levels equal to those of healthy controls after an aortic repair. Ann Vasc Surg. 2006 ; 20 (3). 317-321
26. Eugster T, Huber A, Obeid T, Schwegler I, Gürke L, Stierli P. Aminoterminal propeptide of type III procollagen and matrix metalloproteinases-2 and -9 failed to serve as serum markers for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2005 ; 29 (4). 378-382 (Pubitemid 40340111)
27. Karlsson L, Bergqvist D, Lindbäck J, Pärsson H.. Expansion of small-diameter abdominal aortic aneurysms is not reflected by the release of inflammatory mediators IL-6, MMP-9 and CRP in plasma. Eur J Vasc Endovasc Surg. 2009 ; 37 (4). 420-424
28. Wilson WR, Anderton M, Choke EC, Dawson J, Loftus IM, Thompson MM. Elevated plasma MMP1 and MMP9 are associated with abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg. 2008 ; 35 (5). 580-584 (Pubitemid 351469942)
29. Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T. Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-analysis. Interact Cardiovasc Thorac Surg. 2009 ; 9 (3). 437-440
30. Motaganahalli R, Martin A, Feliciano B, Murphy MP, Slaven J, Dalsing MC.. Estimating the risk of solid organ malignancy in patients undergoing routine computed tomography scans after endovascular aneurysm repair. J Vasc Surg.:
31. Paraskevas KI, Mikhailidis DP, Veith FJ. Patients with peripheral arterial disease, abdominal aortic aneurysms and carotid artery stenosis are at increased risk for developing lung and other cancers. Int Angiol. 2012 ; 31 (4). 404-405
32. Jaumdally RJ, Lip GY, Varma C, Blann AD. Impact of high-dose atorvastatin on endothelial, platelet, and angiogenic indices: effect of ethnicity, cardiovascular disease, and diabetes. Angiology. 2011 ; 62 (7). 571-578
33. Tsantila N, Tsoupras AB, Fragopoulou E, Antonopoulou S, Iatrou C. Demopoulos CA. In vitro and in vivo effects of statins on platelet-activating factor and its metabolism. Angiology. 2011 ; 62 (3). 209-218
34. Paraskevas KI, Veith FJ, Liapis CD, Mikhailidis DP.. Perioperative/ periprocedural effects of statin treatment for patients undergoing vascular surgery or endovascular procedures: an update. Curr Vasc Pharmacol.:
35. Tziomalos K, Athyros V, Karagiannis A, Mikhailidis DP. Lipid lowering agents and the endothelium: an update after 4 years. Curr Vasc Pharmacol. 2012 ; 10 (1). 33-41
36. Paraskevas KI, Mikhailidis DP, Roussas N, Giannoukas AD. Effect of antiplatelet agents, statins, and other drugs on vascular access patency rates. Angiology. 2012 ; 63 (1). 5-8
37. Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des. 2007 ; 13 (35). 3622-3636 (Pubitemid 350238933)
38. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Are statins an option in the management of abdominal aortic aneurysms?. Vasc Endovascular Surg. 2008 ; 42 (2). 128-134 (Pubitemid 351550928)
39. Wilson WR, Evans J, Bell PR, Thompson MM. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2005 ; 30 (3). 259-262 (Pubitemid 41086295)
40. Evans J, Powell JT, Schwalbe E, Loftus IM, Thompson MM. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg. 2007 ; 34 (3). 302-303 (Pubitemid 47194427)
41. Takigawa M, Yoshimuta T, Akutsu K, Takeshita S, Yokoyama N. Prevalence and predictors of coexistent silent atherosclerotic cardiovascular disease in patients with abdominal aortic aneurysm without previous symptomatic cardiovascular diseases. Angiology. 2012 ; 63 (5). 380-385
42. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins - clinical evidence. Curr Pharm Des. 2009 ; 15 (5). 479-489
43. Chase AJ, Newby AC. Regulation of matrix metalloproteinase (matrixin) genes in blood vesssels: a multi-step recruitment model for pathological remodelling. J Vasc Res. 2003 ; 40 (4). 329-343 (Pubitemid 37188102)
44. Whayne TF. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators. Angiology. 2011 ; 62 (5). 413-421
45. Unno N, Nakamura T, Mitsuoka H, et al. Association of a G994àT missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese. Ann Vasc Surg. 2002 ; 235 (2). 297-302 (Pubitemid 34111961)
46. Shah A, Stavropoulos SW. Imaging Surveillance following Endovascular Aneurysm Repair. Semin Intervent Radiol. 2009 ; 26 (1). 10-16